Skip to main content
BIONIME logo

BIONIME — Investor Relations & Filings

Ticker · 4737 ISIN · TW0004737002 TW Manufacturing
Filings indexed 1,740 across all filing types
Latest filing 2024-01-09 Regulatory Filings
Country TW Taiwan
Listing TW 4737

About BIONIME

www.bionime.com

Bionime Corporation is a biotechnology firm specializing in the research, design, and manufacturing of comprehensive blood glucose management systems. The company develops high-precision monitoring solutions for both personal home use and professional medical environments, including Blood Glucose Meters (BGM), Continuous Glucose Monitoring Systems (CGM), and Point-of-Care Testing (POCT). Under its proprietary brand, RIGHTEST, Bionime integrates medical, chemical, electronic, and precision machinery expertise to deliver products that rival international standards. A core component of its offering is a cloud-based management ecosystem powered by IoT digital solutions, which synchronizes medical data with patient care services. With over 480 core patents in CGM technology and a commitment to Industry 4.0 smart production, Bionime focuses on enhancing diabetes care through technical innovation and a human-centered approach to health monitoring.

Recent filings

Filing Released Lang Actions
112年12月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a company named 華廣, providing information about fund loans and endorsement guarantees for the current and previous months, with amounts all zero. The content is very short (601 characters) and consists mainly of tabular data about financial guarantees and loans, without detailed financial statements or analysis. It does not contain any comprehensive financial report or management discussion. It appears to be a regulatory disclosure or compliance update rather than a full report. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-09 Chinese
112年12月董事會成員及持股
Major Shareholding Notification Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by insiders, including directors, independent directors, general manager, and other executives of the company 華廣生技股份有限公司. It lists share counts at appointment and current holdings, pledged shares, and related ratios. The content focuses on insider shareholdings and pledges, which is typical of a Director's Dealing or insider shareholding notification. There is no indication of financial results, management discussion, voting results, or other report types. The document length is about 3,197 characters, which is short and focused on insider shareholding data. Therefore, the best fitting category is Major Shareholding Notification (MRQ), which covers notifications of changes or status of significant share ownership by insiders or major shareholders.
2024-01-04 Chinese
112年12月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document contains detailed tables listing shareholdings of insiders, including directors, executives, and their related parties. It shows the number of shares held, increases and decreases in holdings, and other related information. This type of document is typical of a Director's Dealing report, which discloses personal share transactions by company directors and executives. There is no indication of financial statements, earnings data, or other report types. The document is not an announcement of a report but the actual disclosure of insider shareholdings and transactions.
2024-01-04 Chinese
112年12月變更登記
Share Issue/Capital Change Classification · 95% confidence The document contains detailed information about the company's capital structure, including authorized capital, paid-in capital, capital increases, capital reductions, and dates of regulatory approvals. It is a structured disclosure of share capital changes and related data. The document length is short (861 characters) and it does not contain financial statements or management discussion. It is not an announcement of a report publication but a direct disclosure of capital information. This matches the definition of a Share Issue/Capital Change (SHA) filing, which covers announcements regarding new share issues, stock splits, or other capital changes.
2023-12-22 Chinese
112年11月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (華廣) providing information about fund loans and endorsement guarantees, all showing zero balances. It is very short (601 characters) and contains tabular data about financial limits and balances but no detailed financial statements or analysis. It does not present a full report but rather a regulatory disclosure of specific financial information. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-08 Chinese
112年11月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 華廣, presented in a tabular format with explanations about accounting standards and reporting practices. It contains no detailed financial statements, management discussion, or comprehensive analysis. The length is short (777 characters), and it does not present a full financial report but rather a brief revenue summary. This fits best with a Fund Information / Factsheet (FS) category, which is a brief summary of key company financials and market info. It is not an announcement or publication notice, nor a detailed report like an Annual or Interim Report.
2023-12-08 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.